Nicotine - Older Adults (50+): Difference between revisions

Line 1:

Header

=~~Potential~~ Therapeutic Benefits=

=Smoking Cessation=

=Smokeless Products=

===Snus===

====2021: [https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-021-01979-6 Swedish snuff (snus) and risk of cardiovascular disease and mortality: prospective cohort study of middle-aged and older individuals]====

*In this middle-aged and elderly Swedish population, current Swedish snus use was not associated with the risk of major heart and valvular diseases, abdominal aortic aneurysm, or CVD mortality in the entire study population, but was linked to an increased risk of stroke in never smokers.

**Citation: Titova OE, Baron JA, Michaëlsson K, Larsson SC. Swedish snuff (snus) and risk of cardiovascular disease and mortality: prospective cohort study of middle-aged and older individuals. BMC Med. 2021 May 7;19(1):111. doi: 10.1186/s12916-021-01979-6. PMID: 33957912; PMCID: PMC8103653.

***Acknowledgements: Work of the authors is supported by grants from the Geriatric Foundation, research for healthy aging, and Börjeson, Emil and Ragna Foundation (to O.E.T.), the Swedish Research Council for Health, Working Life and Welfare (Forte; grant number 2018-00123) (to S.C.L.), the Swedish Research Council (Vetenskapsrådet; grant number 2016-01042 and 2019-00977) (to S.C.L.), and the Swedish Heart-Lung Foundation (Hjärt-Lungfonden; grant number 20190247) (to S.C.L.). The study was also supported by additional grants from the Swedish Research Council (https://www.vr.se; grant no 2015-03257, 2017-00644 and 2017-06100 to KM). SIMPLER receives funding through the Swedish Research Council under the grant no 2017-00644 (to Uppsala University and KM). SNIC is financially supported by the Swedish Research Council. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Open Access funding provided by Uppsala University.

=Therapeutic Benefits=

===Memory===

@@ Line 1: / Line 1: @@
 Header
-=Potential Therapeutic Benefits=
+=Smoking Cessation=
+=Smokeless Products=
+===Snus===
+====2021: [https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-021-01979-6 Swedish snuff (snus) and risk of cardiovascular disease and mortality: prospective cohort study of middle-aged and older individuals]====
+*In this middle-aged and elderly Swedish population, current Swedish snus use was not associated with the risk of major heart and valvular diseases, abdominal aortic aneurysm, or CVD mortality in the entire study population, but was linked to an increased risk of stroke in never smokers.
+**Citation: Titova OE, Baron JA, Michaëlsson K, Larsson SC. Swedish snuff (snus) and risk of cardiovascular disease and mortality: prospective cohort study of middle-aged and older individuals. BMC Med. 2021 May 7;19(1):111. doi: 10.1186/s12916-021-01979-6. PMID: 33957912; PMCID: PMC8103653.
+***Acknowledgements: Work of the authors is supported by grants from the Geriatric Foundation, research for healthy aging, and Börjeson, Emil and Ragna Foundation (to O.E.T.), the Swedish Research Council for Health, Working Life and Welfare (Forte; grant number 2018-00123) (to S.C.L.), the Swedish Research Council (Vetenskapsrådet; grant number 2016-01042 and 2019-00977) (to S.C.L.), and the Swedish Heart-Lung Foundation (Hjärt-Lungfonden; grant number 20190247) (to S.C.L.). The study was also supported by additional grants from the Swedish Research Council (https://www.vr.se; grant no 2015-03257, 2017-00644 and 2017-06100 to KM). SIMPLER receives funding through the Swedish Research Council under the grant no 2017-00644 (to Uppsala University and KM). SNIC is financially supported by the Swedish Research Council. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Open Access funding provided by Uppsala University.
+=Therapeutic Benefits=
 ===Memory===